Scott Brian J, Monje Michelle
Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv84-iv94. doi: 10.1093/noajnl/vdaf120. eCollection 2025 Sep.
Cellular Immunotherapies have transformed therapeutic options for individuals with hematologic malignancies over the past 10 years. There are several distinct types of cellular immunotherapies, each with potential applications to CNS cancers. Here, we review cancer cellular therapeutics for cancers of the brain and spinal cord, focusing on the preclinical and clinical studies that have been done in glioblastoma, diffuse intrinsic pontine glioma/diffuse midline glioma, medulloblastoma and lymphoma involving the central nervous system. Numerous potential therapeutic targets have been identified, and several early clinical trials have demonstrated safety and feasibility of administering CAR T and CAR NK cells for intracranial tumors. Addressing mechanisms of treatment failure, while safely and effectively studying the most promising therapies will advance the treatment landscape for these extremely challenging diseases.
在过去十年中，细胞免疫疗法改变了血液系统恶性肿瘤患者的治疗选择。细胞免疫疗法有几种不同类型，每种都有应用于中枢神经系统癌症的潜力。在这里，我们综述用于脑和脊髓癌症的癌症细胞疗法，重点关注胶质母细胞瘤、弥漫性脑桥内在胶质瘤/弥漫性中线胶质瘤、髓母细胞瘤和累及中枢神经系统的淋巴瘤的临床前和临床研究。已经确定了许多潜在的治疗靶点，并且一些早期临床试验已经证明了给予嵌合抗原受体（CAR）T细胞和CAR自然杀伤（NK）细胞治疗颅内肿瘤的安全性和可行性。在安全有效地研究最有前景的疗法的同时，解决治疗失败的机制将推动这些极具挑战性疾病的治疗进展。
